For example, administration of growth hormone to those with short stature due to panhypopituitarism is considered treatment, while administering growth hormone to those with idiopathic short stature is considered enhancement, although the difference in purpose can be quite subtle [9]. Here, GH1 is linked to panhypopituitarism.